This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Chlamydia trachomatis (serotypes D,E,F,G,H,I,J,K)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Chlamydia trachomatis is a Gram-negative obligate intracellular organism. Genital chlamydial infection is the commonest sexually transmitted bacterial infection in the UK (1).

One half of the infected men and around 70% of infected women are asymptomatic (2). Two third of the sexual partners of chlamydia-positive individuals are also positive for chlamydia infections (1).

The serotypes D-K may be acquired in neonates from the birth canal, giving rise to inclusion conjunctivitis.

In adults, infection is acquired by sexual contact causing:

  • in men:
    • urethritis
    • epididymitis
    • proctitis
    • arthritis

  • in women:
    • cervicitis
    • urethritis
    • pelvic inflammatory disease
    • arthritis

In women, up to half of all cases of cervicitis and 60% of all pelvic inflammatory disease may be caused by this organism. Ectopic pregnancy and tubal infertility are possible complications of genital chlamydia infection in women (2).

In tissue culture assays, the most active drugs against C. trachomatis are tetracyclines, followed by macrolides, sulphonamides, some quinolones and clindamycin (3).

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.